Sunday, February 1, 2026
16.6 C
Bengaluru

Key Challenges Facing Indian Pharma

Suresh Subramanian, talks about the challenges and way forward for Indian Pharma companies.

Highlights of the discussion:

With the Second Wave hitting India, customers (patients and physicians) will continue to socially distance themselves in the foreseeable future. Pharma must use the field force for reach and relationship and digital for frequency and personalised content for better customer experience.

The pandemic has made doctors adopt Telehealth in a substantial way to shore up their revenues and this will continue to be one of their channels to engage patients. Telehealth along with EMR/EHR, digital therapeutics and wearables is enabling doctors to better care for their patients. There are many ways in which pharma can support the digital evolution of doctors.

Most pharma companies have multiple divisions and the data from these divisions remain in silos and need to be integrated to better understand customers, their needs and build personas that enable wider segmentation for personalisation of communications.

Data will become the New Supervisor and field sales managers will have to transform into Customer Experience Managers and Medical Reps will have to evolve into Media Planners to be able to connect with doctors based on their channel preferences.

As more and more people search the Internet in their efforts to self-manage, Wellness sector will gain momentum and this is where pharma can work with other partners to provide health related information and products via digital channels to people who are online 24×7.

Some questions that Suresh Subramanian will answer in today’s session:

Register now to receive your email invitation – https://www.credoweb.in/discussion/630/key-challenges-facing-pharma-industry-and-the-way-forward

You can listen to 50+ webinars and Q&A sessions by over 20 thought leaders from India and broad on a wide range of topics that impact pharma business.

Hot this week

IQVIA vs. PharmaTrac: Indian Pharma Market Data

Here is an analytical blog comparing the IQVIA MFR...

Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead

The latest PharmaTrac report for December 2025 offers a...

Orphan Drugs and Indian Pharma: Moving from Volume to Value?

Zydus’ ZYCUBO May Be the Proof Point the Industry...

Arjun Arunachalam: The Man Who Deleted Helium

For more than fifty years, the MRI industry treated...

Who Is Monitoring Quality in India’s Small Drug Units?

The Telangana Drugs Control Administration’s stop-use notice on a...

Topics

IQVIA vs. PharmaTrac: Indian Pharma Market Data

Here is an analytical blog comparing the IQVIA MFR...

Orphan Drugs and Indian Pharma: Moving from Volume to Value?

Zydus’ ZYCUBO May Be the Proof Point the Industry...

Arjun Arunachalam: The Man Who Deleted Helium

For more than fifty years, the MRI industry treated...

Who Is Monitoring Quality in India’s Small Drug Units?

The Telangana Drugs Control Administration’s stop-use notice on a...

Zydus vs. Helsinn — What It Really Means for Indian Pharma

On December 24, 2025, the Delhi High Court delivered...

Worldclass Healthcare But Out of Reach for Most Indians?

When an eminent cardiologist like Dr. Sunil Chandy—former Director...

Managed Healthcare – Better Choice for India?

Managed care shifts healthcare from fragmented fee-for-service models to...
spot_img

Related Articles

spot_imgspot_img